{"organizations": [], "uuid": "ad3f568692c48ca10a7217386084cc8ea5479045", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180123.html", "section_title": "Archive News &amp; Video for Tuesday, 23 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-voyager-therapeutics-announces-fda/brief-voyager-therapeutics-announces-fda-clearance-of-investigational-nda-for-vy-aadc-idUSASB0C1UT", "country": "US", "domain_rank": 408, "title": "BRIEF-Voyager Therapeutics Announces FDA Clearance Of Investigational NDA For VY-AADC", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.265, "site_type": "news", "published": "2018-01-23T20:08:00.000+02:00", "replies_count": 0, "uuid": "ad3f568692c48ca10a7217386084cc8ea5479045"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-voyager-therapeutics-announces-fda/brief-voyager-therapeutics-announces-fda-clearance-of-investigational-nda-for-vy-aadc-idUSASB0C1UT", "ord_in_thread": 0, "title": "BRIEF-Voyager Therapeutics Announces FDA Clearance Of Investigational NDA For VY-AADC", "locations": [], "entities": {"persons": [{"name": "parkinson", "sentiment": "none"}], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "fda clearance of investigational nda", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 23 (Reuters) - Voyager Therapeutics Inc:\n* VOYAGER THERAPEUTICS ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR VY-AADC FOR ADVANCED PARKINSON’S DISEASE\n* VOYAGER THERAPEUTICS INC - CONTINUE TO PLAN TO DOSE FIRST PATIENT IN PIVOTAL PHASE 2-3 PROGRAM FOR ADVANCED PARKINSON‘S DISEASE DURING Q2 Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-23T20:08:00.000+02:00", "crawled": "2018-01-24T15:36:47.000+02:00", "highlightTitle": ""}